Dongshan Zhang

16PUBLICATIONS

21CO-AUTHORS

Molecular targetsPredictive and prognostic markersUrban community developmentApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Infant and child health

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (16)

Sort by Publication Date:

|Jul 13, 2026

Multiple organ dysfunction syndrome: molecular mechanisms and therapeutic strategies.

|Mar 30, 2026

PRDM16 protects retinal ganglion cells from ischemia-reperfusion Injury by regulating the RPL5/p53 axis.

Yuqing Feng, Zhou Li, Jinfang Lu

|Mar 06, 2026

Acute kidney injury over the past decade: from definition evolution to pathogenesis insights and innovative therapeutic strategies.

Jinwen Chen, Xuan Xu, Yifang Cai

|Jul 08, 2025

Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial.

Zijing Liang, Si Liu, Wei Guo

|Jun 23, 2025

PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6.

Xiaozhou Li, Yang Xia, Xingjin Li

|Apr 02, 2025

PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10.

Bocheng Han, Qiang Zheng, Huiling Li

Pageof 3

Frequent Collaborators

Yinhuai Wang

Yong Guo

Dengke Wu

Xiaozhou Li

Juan Wang

Huiling Li

Yijian Li

Dan Luo

Feng Yi

Xinyu Liu

Frequent Collaborators

Yinhuai Wang

Yong Guo

Dengke Wu

Xiaozhou Li